13 September 2024
Futura Medical
plc
("Futura" or the
"Company")
Directors' / PDMR
Dealing
Futura Medical plc (AIM: FUM), the
consumer healthcare company behind Eroxon, that specialises in the
development and global commercialisation of innovative
and clinically proven sexual health products, announces that
it has received notice to exercise options from James Barder,
CEO and Ken James, executive Head of R&D to exercise 500,000
options over ordinary shares of 0.2 pence in the Company
("Ordinary Shares").
The following options have been
exercised:
|
Director
|
Number of Options exercised
|
Status
|
Exercise price
|
Total number of Options held following
exercise
|
|
James Barder
|
250,000
|
Unapproved
|
30.50p
|
|
|
James Barder
|
50,000
|
EMI
|
15.50p
|
3,660,927
|
|
Ken James
|
200,000
|
EMI
|
30.50p
|
3,455,955
|
James Barder has sold 250,000
Ordinary Shares the proceeds of which will be used to satisfy the
tax liability and the exercise of 50,000 options with an exercise
price of 15.50p, these shares will be retained by James. In
addition, Ken James has sold 200,000 Ordinary Shares.
Following these
transactions James
Barder's interests in Ordinary Shares is 1,470,972 Ordinary
Shares, representing approximately 0.5% of
the Company's issued share capital. Ken James' interests in
Ordinary Shares of 299,581 Ordinary Shares representing
approximately 0.1% of the Company's issued share capital remains
unchanged.
450,000 options with an exercise
price of 30.50p would lapse on 30 September 2024, if not
exercised.
Further disclosures are contained in
the tables below.
Total Voting Rights
Following the issue of 500,000
Ordinary Shares under the Company's existing block listings to
satisfy the exercise of options, for the purposes of
the FCA's Disclosure and Transparency Rules, the
Company's total issued share capital at the date of this
announcement is 302,363,641 Ordinary Shares.
Since the Company currently holds no
shares in treasury, the total number of voting rights in the
Company is 302,363,641 and this figure may therefore be used by shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the share capital of the Company under
the FCA's Disclosure and Transparency Rules.
ENDS
Contacts:
|
Futura Medical plc
|
James Barder
Chief Executive Officer
Angela Hildreth
Finance Director and COO
|
investor.relations@futuramedical.com
+44 (0)1483 685 670
www.futuramedical.com
|
|
Panmure Liberum
Nominated Adviser
and Broker
|
Emma Earl, Will
Goode, Mark Rogers (Corporate Finance)
Rupert Dearden (Corporate
Broking)
|
+44 (0)20 3100 2000
|
|
|
|
|
|
Stifel Nicolaus Europe Limited
Joint Broker
|
Alan Selby
Ben Maddison
|
+44 (0)207 710 7600
|
|
|
|
|
|
Alma Strategic Communications
|
Rebecca Sanders-Hewett
Sam Modlin
Will Ellis Hancock
|
+44 (0)20 3405 0205
futura@almastrategic.com
|
|
|
|
|
Notes to Editors:
Futura Medical plc (AIM: FUM)
is the developer of innovative sexual health products, including
lead product Eroxon. Our core strength lies in our research,
development and commercialisation of topically delivered gel
formulations in sexual health products.
Eroxon, Futura's clinically proven
lead product, has been developed for the treatment of Erectile
Dysfunction ("ED"). The highly differentiated product,
which is the only topical gel treatment for ED available over the
counter and helps men get an erection in ten
minutes, addresses significant unmet needs in the ED
market.
ED impacts 1 in 5 men globally
across all adult age brackets, with approximately half of all men
over 40 experiencing ED and 25% of all new diagnoses being in men
under 40.
Futura has distribution partners in
place in a number of major consumer markets including Haleon in the
US, the largest market for ED in the world, and Cooper
Consumer Health in Europe. Eroxon has been nominated for
a number of healthcare industry awards and has won two
to-date.
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a)
|
Name
|
James Barder
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Executive Officer
|
|
b)
|
Initial
notification/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Futura Medical plc
|
|
b)
|
LEI
|
21380053QLT46UNV2303
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary shares at 0.2p
each
GB0033278473
|
|
b)
|
Nature of the transaction
|
1. Exercise of options with
exercise price of 30.50p
2. Disposal of 250,000 ordinary
shares following exercise
3. Exercise of 50,000 options with
exercise price of 15.50p
|
|
c)
|
Price(s) and volume(s)
|
|
|
Price(s)
|
Volume(s)
|
|
1.
|
30.50p
|
250,000
|
|
2.
|
40.6628p
|
250,000
|
|
3.
|
15.50p
|
50,000
|
|
|
d)
|
Aggregated information
- Aggregated
volume
-
Price
|
1. 250,000
2. 250,000
3. 65,000
1. £76,250.00
2. £101,657.00
3. £7,750
|
|
e)
|
Date of the transaction
|
12 September 24
|
|
f)
|
Place of the transaction
|
1. Outside a trading
venue
2. XLON
3. Outside a trading
venue
|
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a)
|
Name
|
Ken James
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Executive Director
and Head of R&D
|
|
b)
|
Initial
notification/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Futura Medical plc
|
|
b)
|
LEI
|
21380053QLT46UNV2303
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary shares at 0.2p
each
GB0033278473
|
|
b)
|
Nature of the transaction
|
1. Exercise of options with
exercise price of 30.50p
2. Disposal of 200,000 ordinary
shares following exercise
|
|
c)
|
Price(s) and volume(s)
|
|
|
Price(s)
|
Volume(s)
|
|
1.
|
30.50p
|
200,000
|
|
2.
|
40.6628p
|
200,000
|
|
|
d)
|
Aggregated information
- Aggregated
volume
-
Price
|
1. 200,000
2. 200,000
1. £61,000.00
2. £81,325.60
|
|
e)
|
Date of the transaction
|
12 September 2024
|
|
f)
|
Place of the transaction
|
1. Outside a trading
venue
2. XLON
|